16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships.
University Of T£Bingen
Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.
H. Lee Moffitt Cancer Center And Research Institute
Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.
University Of Kansas
Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.
University Of Kansas
Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides.
University Of Kansas
Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids.
Eisai Research Institute
Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines.
University Of Auckland
Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim.
University Of Pittsburgh
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[
Glaxosmithkline
Synthesis of urea analogues bearing N-alkyl-N'-(thiophen-2-yl) scaffold and evaluation of their innate immune response to toll-like receptors.
Southern Medical University
Identification of Human Toll-like Receptor 2-Agonistic Activity in Dihydropyridine-Quinolone Carboxamides.
University Of Minnesota
Decoy peptides derived from the extracellular domain of toll-like receptor 2 (TLR2) show anti-inflammatory properties.
Medical University Innsbruck
Site-specific effect of polar functional group-modification in lipids of TLR2 ligands for modulating the ligand immunostimulatory activity.
Keio University
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.
University Of Colorado Boulder
